Last Updated:
July 1, 2024

Immunisation for adults with HIV infection v9

From 1 July, Shingrix eligibility has changed. Please see Pharmac Schedule. This resource will be updated to reflect changes as soon as possible. This factsheet provides guidance to support the immunisation of adults with HIV infection.

Download resource

Overview

Human immunodeficiency virus (HIV) infects CD4+T cells leading to a progressive decline in CD4 cell count, increasing immunodeficiency and vulnerability to infection, and suboptimal responses to vaccines. Use of antiretroviral therapy (ART) to reduce virus replication and improve CD4 counts to 200cells/mm3 or higher, preferably above 400cells/mm3, is recommended to improve the response to all vaccines.

For children aged under 18 years, please refer to the current Immunisation Handbook.



Cartoon image of a man showing his arm where he received a vaccination

Overview

Human immunodeficiency virus (HIV) infects CD4+T cells leading to a progressive decline in CD4 cell count, increasing immunodeficiency and vulnerability to infection, and suboptimal responses to vaccines. Use of antiretroviral therapy (ART) to reduce virus replication and improve CD4 counts to 200cells/mm3 or higher, preferably above 400cells/mm3, is recommended to improve the response to all vaccines.

For children aged under 18 years, please refer to the current Immunisation Handbook.

Download

Download PDF



Last updated:
Jul 2024